Clinical Trials · NCT02203331
Bay98-7196, Dose Finding / POC Study
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Bayer
- Enrollment
- 319
- Start date
- Oct 2014
- Locations
- 117 sites, 14 countries
- Primary endpoint
- Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD